Gain Therapeutics, Inc. - GANX STOCK NEWS

Gain Therapeutics (NASDAQ: GANX) recently reported its third-quarter financial results, highlighting a net loss of $4.56 million and cash reserves of $25.7 million as of September 30, 2022. The company presented promising preclinical data for GT-02287, its lead candidate for Parkinson's disease, demonstrating potential disease-modifying effects, including improved motor skills in mice. Gain anticipates beginning its Phase 1 clinical trial in mid-2023, leveraging its strong financial foundation to advance its research programs.

Gain Therapeutics (NASDAQ: GANX) announced positive preclinical data for its investigational small molecule therapeutic, GT-02287, targeting Parkinson’s Disease. Presented at the Shaare Zedek Medical Center symposium, the study demonstrated significant increases in GCase levels and reductions in α-synuclein aggregates using patient-derived neurons. This suggests GT-02287 may correct GBA1 mutations, which affect 14% of Parkinson's patients. The findings support GT-02287's potential as a disease-modifying treatment, reinforcing Gain's approach using its proprietary computational drug discovery platform.

Gain Therapeutics, Inc. (NASDAQ: GANX) has appointed Matthias Alder as its new Chief Executive Officer, effective immediately, following the departure of Eric Richman, who will remain on the board and serve as a senior advisor. Alder, the former Chief Operating Officer, brings over 25 years of experience in the pharmaceutical sector. His leadership is anticipated to drive the company's growth strategy and advance key programs targeting Parkinson's and Gaucher diseases. The board size has increased to eight members with Alder's appointment.

Gain Therapeutics (Nasdaq: GANX) presented preclinical data on GT-02287 at the International Congress of Parkinson’s Disease and Movement Disorders 2022 Annual Meeting. Results demonstrated a significant dose-dependent improvement in lysosomal health and fine motor skills in Parkinson’s disease models. GT-02287 shows promise in neutralizing CBE-mediated neurodegeneration and enhancing neuronal survival. This research indicates the potential for GT-02287 as a first-in-class disease-modifying therapy, aiming to restore enzyme function in Parkinson’s patients.

Gain Therapeutics, Inc. (Nasdaq: GANX) is set to present preclinical data at two significant medical meetings in September 2022. The first presentation will occur at the MDS 2022 International Congress in Madrid on September 17, featuring a poster on GT-02287, a promising allosteric regulator for Parkinson's disease. The second presentation will be at the GBA-PD Symposium in Jerusalem on September 22, discussing innovative strategies for GBA-PD. Gain's approach employs its unique computational discovery platform, SEE-Tx®, to drive advancements in drug development.

Gain Therapeutics (Nasdaq: GANX) announced that COO Matthias Alder will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, in New York. The presentation is scheduled for September 12 at 7:00 AM ET and will be available via a webcast. Gain Therapeutics focuses on transforming drug discovery with its proprietary SEE-Tx® platform, targeting allosteric binding sites to develop treatments for various diseases, including neurodegenerative and metabolic disorders.

Gain Therapeutics, Inc. (Nasdaq: GANX) announced its participation in the 2022 BTIG Biotechnology Conference on August 9 at 12 p.m. ET. The event will take place in New York City on August 8-9. The company will engage in a fireside chat and host investor meetings. Gain's unique computational platform, SEE-Tx®, identifies novel allosteric binding sites to revolutionize drug discovery, targeting diseases like Parkinson’s. Their work has garnered funding from notable organizations, including The Michael J. Fox Foundation.

Gain Therapeutics, Inc. (Nasdaq: GANX) is set to present at the Jefferies Healthcare Conference from June 8-10, 2022, in New York, NY. COO Matthias Alder will host a corporate presentation on June 10 at 8:00 AM ET, with a live webcast available on the company's website. Gain Therapeutics focuses on transforming drug discovery through its proprietary technology, SEE-Tx®, which identifies novel allosteric binding sites for various diseases. Their pipeline targets neurodegenerative diseases, lysosomal storage disorders, and oncology, with significant funding support for their Parkinson’s disease program.

Gain Therapeutics, Inc. (Nasdaq: GANX) will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 1:30 PM ET. CEO Eric Richman is set to lead the corporate presentation and host one-on-one meetings during the event, which runs from May 23-25 in Miami, Florida. Gain is known for its innovative drug discovery platform that targets allosteric binding sites to create small molecule treatments for various diseases, including neurodegenerative disorders. A live webcast will be available on their website, and an archived version will follow.